1. Merck launched Biosimilars Clarified, a new online resource about biosimilars for patients and healthcare providers. The drugmaker is currently partnering with Samsung Bioepis to bring biosimilars of AbbVie’s Humira, Roche’s Herceptin, and Sanofi’s Lantus to market.
2. The price of branded insulin continues to rise even as new competitors emerge. Prices of competing insulins have gone up in lockstep. The annual cost of insulin reached $736 annually per patient in 2013 — a threefold hike from 2002. (STAT)
3. The National Institute for Health and Care Excellence said in draft guidance that it will not fund Bristol-Myers Squibb’s Opdivo as a treatment for non-small cell lung cancer. The U.K. cost watchdog said it was weighing use of the drug to collect more data on its effectiveness, but only for patients with high expression of the PD-L1 protein in their tumors. (PharmaTimes)
4. BioMarin is mulling an appeal of the FDA’s rejection of its experimental drug for Duchenne muscular dystrophy, drisapersen. The agency recently approved the first drug to treat Duchenne muscular dystrophy, Sarepta Therapeutics’ Exondys 51. (Endpoints News)
5. Despite the growing threat of antibiotic resistance and superbugs, drugmakers continue to market antibiotics to farmers. New FDA rules intended to curb the use of antibiotics will go into effect in January. In anticipation, drugmakers have launched educational webinars to help farmers comply with these new regulations and continue to receive antibiotics. (Bloomberg)